Vyvanse’s Long Shadow: Launch To Decide Fate Of Two Other Shire Drugs
Executive Summary
Shire is keeping two pending NDAs for new attention deficit hyperactivity disorder treatments in a sort of limbo while it waits to see if the high expectations for the launch of its d-amphetamine prodrug Vyvanse are fulfilled